Lin, H.-J.; Liang, T.-L.; Chang, Y.-Y.; Liu, D.-Z.; Fan, J.-Y.; Roffler, S.R.; Lin, S.-Y.
Development of Irinotecan Liposome Armed with Dual-Target Anti-Epidermal Growth Factor Receptor and Anti-Fibroblast Activation Protein-Specific Antibody for Pancreatic Cancer Treatment. Pharmaceutics 2022, 14, 1202.
https://doi.org/10.3390/pharmaceutics14061202
AMA Style
Lin H-J, Liang T-L, Chang Y-Y, Liu D-Z, Fan J-Y, Roffler SR, Lin S-Y.
Development of Irinotecan Liposome Armed with Dual-Target Anti-Epidermal Growth Factor Receptor and Anti-Fibroblast Activation Protein-Specific Antibody for Pancreatic Cancer Treatment. Pharmaceutics. 2022; 14(6):1202.
https://doi.org/10.3390/pharmaceutics14061202
Chicago/Turabian Style
Lin, Hung-Jun, Tien-Li Liang, Yao-Yuan Chang, Der-Zen Liu, Jia-Yu Fan, Steve R. Roffler, and Shyr-Yi Lin.
2022. "Development of Irinotecan Liposome Armed with Dual-Target Anti-Epidermal Growth Factor Receptor and Anti-Fibroblast Activation Protein-Specific Antibody for Pancreatic Cancer Treatment" Pharmaceutics 14, no. 6: 1202.
https://doi.org/10.3390/pharmaceutics14061202
APA Style
Lin, H. -J., Liang, T. -L., Chang, Y. -Y., Liu, D. -Z., Fan, J. -Y., Roffler, S. R., & Lin, S. -Y.
(2022). Development of Irinotecan Liposome Armed with Dual-Target Anti-Epidermal Growth Factor Receptor and Anti-Fibroblast Activation Protein-Specific Antibody for Pancreatic Cancer Treatment. Pharmaceutics, 14(6), 1202.
https://doi.org/10.3390/pharmaceutics14061202
